Clinical trials: Scalp Psoriasis
Psoriasis
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
- Trial name
- NCT07340216
- Testing
- ARQ-154 Foam 0.3%
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Psoriasis of Scalp
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment of calcipotriol scalp solution in patients…
- Trial name
- NCT00243464
- Testing
- Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
- Where
- 5 sites in Belgium, Canada and 3 more
- Volunteers
- 300 people
- Sponsor
- LEO Pharma
Psoriasis Palmaris, Psoriasis Genital
Efficacy of Tildrakizumab in Difficult-to-treat Areas in Psoriasis
Psoriasis is a chronic inflammatory disease that affects between 2% and 4% of the French population.Some specific localizations are more difficult to manage, such as the scalp, nails, genital region and palmoplantar…
- Conditions
- Psoriasis Palmaris, Psoriasis Genital, Psoriasis of Scalp, Psoriasis Plantaris
- Trial name
- ZODIPSO (NCT05938361)
- Testing
- Psoriasis clinical assessments, Quality of life evaluation, Satisfaction assessment
- Where
- France
- Volunteers
- 160 people
- Sponsor
- Clin4all
Psoriasis
A Study to Evaluate the Safety and Efficacy of Efalizumab in Adult Patients With Moderate to Severe Plaque Psoriasis With Involvement of the Scalp
This was a Phase IV randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of subcutaneous efalizumab in adult patients (18 years of age and older) with chronic moderate to severe plaque…
- Trial name
- SCALP (NCT00669214)
- Testing
- efalizumab
- Volunteers
- 89 people
- Sponsor
- Genentech, Inc.
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Scalp Psoriasis
Daxxin Psoriasis Shampoo PMCF
The goal of this clinical investigation is to verify the performance and safety of the CE-marked Daxxin Psoriasis Shampoo to treat scalp psoriasis.
- Trial name
- NCT06771648
- Where
- 2 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Daxxin AB
Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
- Trial name
- ADVANCE (NCT03721172)
- Testing
- Apremilast
- Where
- 64 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- Amgen
Psoriasis
Scalp Psoriasis Treatment With a Fiber Optic Comb
This study will test the safety and effectiveness of a novel fiber optic device for treating scalp psoriasis with ultraviolet (UV-B) light. A effective treatment is not currently available for people with scalp psoriasis.
- Trial name
- NCT00007293
- Testing
- UV-B Lightsource and Fiber Optic Comb
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Scalp Psoriasis
Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis
The purpose of this study is to evaluate efficacy and safety of 0.25% Desoximetasone cream (Topoxy®) compare with 0.25% Desoximetasone cream (Topicorte®) in the treatment of scalp psoriasis.
- Trial name
- NCT02749656
- Testing
- 0.25% Desoximetasone cream (Topoxy®), 0.25% Desoximetasone cream (Topicorte®)
- Where
- Thailand
- Volunteers
- 105 people
- Sponsor
- Siriraj Hospital
Scalp Psoriasis, Pustular Palmo-plantar Psoriasis
IL-17 Role in Variants of Psoriasis
The goal of this project is to study some mechanisms involved in the dysregulation of the immune system observed in the skin of subjects with psoriasis.
- Conditions
- Scalp Psoriasis, Pustular Palmo-plantar Psoriasis, Non-pustular Palmo-plantar Psoriasis, Elbow Psoriasis
- Trial name
- NCT02078297
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Innovaderm Research Inc.
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
- Trial name
- ICONIC-TOTAL (NCT06095102)
- Testing
- JNJ-77242113
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 311 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis, Scalp Psoriasis
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by…
- Trial name
- VISIBLE (NCT05272150)
- Testing
- Guselkumab
- Where
- 94 sites in United States, Canada
- Volunteers
- 211 people
- Sponsor
- Janssen Research & Development, LLC
Scalp Psoriasis
Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)
This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in…
- Trial name
- NCT01052467
- Testing
- Xamiol® Gel
- Where
- Germany
- Volunteers
- 724 people
- Sponsor
- LEO Pharma
Scalp Psoriasis
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 gel in adolescent subjects (aged 12 to 17) with scalp psoriasis.
- Trial name
- NCT01120223
- Testing
- LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
- Where
- 17 sites in Canada, France and 1 more
- Volunteers
- 78 people
- Sponsor
- LEO Pharma
Psoriasis, Psoriatic Arthritis
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01690299
- Testing
- Apremilast, Etanercept
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Psoriasis
Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray
A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis
- Trial name
- NCT02985736
- Testing
- Topicort Topical Spray
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Scalp Psoriasis
Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis
Psoriasis is a serious, immune-driven illness that affects around 2% of the population and has a wide range of clinical manifestations 1-3 .
- Trial name
- NCT06015152
- Testing
- Tazarotene 0.045% Topical Application Lotion [ARAZLO]
- Where
- Pakistan
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Jinnah Postgraduate Medical Centre
Scalp Psoriasis
Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tildrakizumab in the treatment of moderate to severe psoriasis of the scalp.
- Trial name
- NCT03897088
- Testing
- PART 2: Double-blind Active Treatment Extension
- Where
- 25 sites in United States, Australia
- Volunteers
- 231 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Scalp Psoriasis
Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis
The study will be conducted to evaluate the efficacy and safety of a topical dimeticone formulation (Loion®) compared to 10% salicylic acid in octyl-dodecanol with 15% Macrogol-4-laurylether for the removal of scaling in patients…
- Trial name
- NCT01914627
- Testing
- Dimethicone, Salicylic Acid
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- G. Pohl-Boskamp GmbH & Co. KG
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma